中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
Decline in serum progastrin-releasing peptide predicts the response of patients with small cell lung cancer to chemotherapy

文献类型:期刊论文

作者Li, Ming1,3,4; Han, Dandan1; Wang, Wei4; Zhang, Yang1; Li, Dan1; Dai, Chunyang1; Qian, Liting1; Lin, Wenchu2,4
刊名ONCOLOGY LETTERS
出版日期2020-12-01
卷号20
关键词progastrin-releasing peptide therapeutic monitoring small-cell lung cancer neuron-specific enolase
ISSN号1792-1074
DOI10.3892/ol.2020.12164
通讯作者Lin, Wenchu(wenchu@hmfl.ac.cn)
英文摘要The utility of serum progastrin-releasing peptide (ProGRP) and neuron-specific enolase (NSE) as biomarkers for treatment monitoring and as prognostic factors was investigated in small cell lung cancer (SCLC) patients. Patients were first diagnosed pathologically at the First Affiliated Hospital of the University of Science and Technology of China and had their serum ProGRP and NSE levels measured using an electrochemiluminescence immunoassay. A total of 120 SCLC patients were enrolled. In responsive patients, ProGRP levels decreased significantly following two cycles of chemotherapy and continued to decline over the course of treatment. However, this decrease in ProGRP levels was not observed in non-responsive patients. Changes in ProGRP levels were more accurate than changes in NSE levels for monitoring the effects of chemotherapy in patients with SCLC. Following two treatment cycles or after the occurrence of drug resistance, changes in ProGRP levels in patients with low ProGRP levels at the time of diagnosis were not notably, regardless of whether or not patients were responders. The area under the receiver operating characteristic curve of the decline in ProGRP levels as a therapeutic biomarker of SCLC was 0.9643, and the cut-off value was 55.02%. A decline in ProGRP levels maybe a good predictor of objective response to chemotherapy in patients with SCLC with higher ProGRP levels at diagnosis. This model is expected to replace or be combined with imaging to predict chemotherapeutic treatment effects in patients with SCLC.
WOS关键词NEURON-SPECIFIC ENOLASE ; PROGRP ; DIAGNOSIS ; BIOMARKER ; SURVIVAL ; THERAPY ; NSE
资助项目Fundamental Research Funds for the Central University[WK9110000025] ; Natural Science Foundation of Anhui Province[2008085MH288] ; Science and Technology Major Project of Anhui Province[18030801140] ; National Natural Science Foundation of China[81672647] ; National Ministry of Industry and Information Technology Science and Technology[2018MND102041]
WOS研究方向Oncology
语种英语
WOS记录号WOS:000595649300070
出版者SPANDIDOS PUBL LTD
资助机构Fundamental Research Funds for the Central University ; Natural Science Foundation of Anhui Province ; Science and Technology Major Project of Anhui Province ; National Natural Science Foundation of China ; National Ministry of Industry and Information Technology Science and Technology
源URL[http://ir.hfcas.ac.cn:8080/handle/334002/105418]  
专题中国科学院合肥物质科学研究院
通讯作者Lin, Wenchu
作者单位1.Univ Sci & Technol China, Affiliated Hosp 1, Dept Lab Diagnost, Hefei 230031, Anhui, Peoples R China
2.Chinese Acad Sci, Hefei Inst Phys Sci, Key Lab High Magnet Field & Ion Beam Phys Biol, Hefei 230031, Anhui, Peoples R China
3.Univ Sci & Technol China, Hefei 230036, Anhui, Peoples R China
4.Chinese Acad Sci, High Magnet Field Lab, 350 Shushanhu Rd, Hefei 230031, Anhui, Peoples R China
推荐引用方式
GB/T 7714
Li, Ming,Han, Dandan,Wang, Wei,et al. Decline in serum progastrin-releasing peptide predicts the response of patients with small cell lung cancer to chemotherapy[J]. ONCOLOGY LETTERS,2020,20.
APA Li, Ming.,Han, Dandan.,Wang, Wei.,Zhang, Yang.,Li, Dan.,...&Lin, Wenchu.(2020).Decline in serum progastrin-releasing peptide predicts the response of patients with small cell lung cancer to chemotherapy.ONCOLOGY LETTERS,20.
MLA Li, Ming,et al."Decline in serum progastrin-releasing peptide predicts the response of patients with small cell lung cancer to chemotherapy".ONCOLOGY LETTERS 20(2020).

入库方式: OAI收割

来源:合肥物质科学研究院

浏览0
下载0
收藏0
其他版本

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。